Stoke Therapeutics (STOK) Enterprise Value (2022 - 2025)
Stoke Therapeutics has reported Enterprise Value over the past 4 years, most recently at -$84.7 million for Q4 2025.
- Quarterly results put Enterprise Value at -$84.7 million for Q4 2025, up 33.85% from a year ago — trailing twelve months through Dec 2025 was -$84.7 million (up 33.85% YoY), and the annual figure for FY2025 was -$84.7 million, up 33.85%.
- Enterprise Value for Q4 2025 was -$84.7 million at Stoke Therapeutics, down from -$83.4 million in the prior quarter.
- Over the last five years, Enterprise Value for STOK hit a ceiling of -$83.4 million in Q3 2025 and a floor of -$357.3 million in Q1 2025.
- Median Enterprise Value over the past 4 years was -$208.1 million (2023), compared with a mean of -$201.8 million.
- Peak annual rise in Enterprise Value hit 47.53% in 2025, while the deepest fall reached 100.09% in 2025.
- Stoke Therapeutics' Enterprise Value stood at -$229.6 million in 2022, then increased by 12.28% to -$201.4 million in 2023, then soared by 36.41% to -$128.1 million in 2024, then skyrocketed by 33.85% to -$84.7 million in 2025.
- The last three reported values for Enterprise Value were -$84.7 million (Q4 2025), -$83.4 million (Q3 2025), and -$101.5 million (Q2 2025) per Business Quant data.